Is the 2026 Ivermectin Cancer Study Real Evidence or a Red Flag? A Critical Analysis of What Patients Need to Know

Table of Contents

• Introduction
• Semantic Glossary
• What Is the Hulscher 2026 Ivermectin-Cancer Study and Why Is Does an 84.4% ‘Clinical Benefit Rate’ Actually Mean — and What Itancer Research Expression of Concern: Data Verifiability, Statistical Reliability, and Ethical Oversight Questions
• Selling the Product Studied? The Wellness Company’s Commercial Role Explained
• NCI Ivermectin Research vs. the Hulscher Study: Two Completely Different Things
• The Only Registered Human Ivermectin Oncology Trial (NCT05318469): What Is Actually Known

• What Oncologists and Evidence-Based Medicine Say About Ivermectin for Cancer Right Now
• Frequently Asked Questions
• Additional Related Articles
• Conclusion
• Medical Disclaimer
• Sources

---

Introduction

Courage Against Cancer (CAC) is a cancer education nonprofit dedicated to empowering patients, caregivers, and clinicians with evidence-informed resources that support informed, you you are in the middle of treatment and we understand the urgency you feel, and we are committed to giving you honest information that protects your safety and supports your hope.

That commitment is also why CAC supports and sponsors clinical trials into the oncological use patients deserve to know the difference between that kind of investigation and the study examined here.

The short answer to whether the 2026 Hulscher ivermectin-cancer study represents actionable clinical evidence is this: based on our analysis, it does not. As of mid-2026, the study carries an active Expression of Concern from its own publisher and was designed, conducted, and reported entirely by individuals with disclosed financial ties to the sole commercial seller of the product studied. A viral headline circulated widely across social media, generating urgent questions from journal has flagged integrity concerns, how it differs from legitimate NCI prec your oncology team should be asking before acting below, the following six terms are foundational to evaluating any clinical research claim:

Expression of Concern

A formal notice issued by a scientific journal indicating that questions have been raised about a published study’s data integrity, methodology, ethical oversight, or author conduct — serious enough to warrant public disclosure, though not yet rising to the level of a full retraction. It signals that independent readers should interpret the study’s findings with heightened caution.

Observational Study

A type of research in which investigators record outcomes among participants without randomly assigning them to treatment or control groups. Because participants self-select into the intervention being studied, observational studies cannot establish that a treatment caused the outcomes observed.

Self-Reported Outcome

A health outcome measured by patient perception rather than by values, or physician assessment. Self-reported data are subject to recall bias, social desirability bias use of an approved drug for an indication, population, or dose not carries heightened responsibility to communicate uncertainty to patients. enables readers to weigh findings accordingly.

Randomized Controlled Trial (RCT)

The gold-standard study design in clinical medicine, in which participants are randomly assigned to receive either the experimental intervention or a comparator (placebo or standard of care). Randomization controls for confounding variables, enabling researchers to make causal claims about treatment efficacy and safety with greater confidence.

---

What Is the Hulscher 2026 Ivermectin-Cancer Study and Why Is It Going Viral?

In June 2026, Anticancer Research published a study by Hulscher et al. examining off-label use of a compounded ivermectin-plus-mebendazole form social interest — and urgent, deeply human questions from

• The limited options
• Ivermectin already carries cultural fam indexed oncology journal
• Claims referenced a combination therapy (ivermectin + mebendazole) with a pl regardless of methodological context

**What the study does to a control group

• FDA-recognized efficacy for any onc why a study goes viral is itself a critical health literacy skill. As with all circulating oncology claims, you from noise — a core part of CAC’s educational mission. And because CAC supports and sponsors clinical trials into the oncological use and efficacy of ivermectin and mebendazole, we have a particular responsibility to be clear-eyed about what the current commercial-interest study does and does not show. Understanding what ivermectin is currently approved to treat provides essential context for evaluating any claims made about its use in oncology settings.

---

Breaking Down the Study Design: Why Observational and Self-Reported Data Have Serious Limits

The Hulscher et al. study used an observational, non-randomized design with self-reported primary outcomes — a methodological combination patients, survivors, and caregivers.

**Core designator arm receiving standard of care or placebo, it is impossible to know whether outcomes differed from what would have occurred without ivermectin-mebendazole.

• **High at introduces serious selection bias, as completers are not equivalent to the full enrolled population.
• Self-reported primary outcomes. Patient-perceived benefit is not equivalent to objective tumor response measurements.
• Heterogeneous tumor types. Pooling diverse cancers obscures whether any signal exists in specific histologies.
• No blinding. Both.

If you are a recently diagnosed patient or caregiver reading this, these design limitations do not mean the underlying science of ivermectin and mebendazole in cancer is without merit — CAC’s own sponsored trials are designed precisely to answer that question rigorously. They do mean that this particular study cannot tell you whether the treatment works. For a deeper understanding of how cancer clinical trial design affects the reliability of treatment evidence, the National Cancer Institute provides accessible educational resources on trial phases and controls.

---

What Does an 84.4% ‘Clinical Benefit Rate’ Actually Mean — and What It Doesn’t

The phrase “84.4% clinical benefit rate” deserves careful parsing. As a patient, survivor, or caregiver, understanding what this number actually by themselves

• “Clinical benefit” was not defined by objective tumor response criteria such as RECIST (Response Evaluation Criteria in Solid Tumors)
• No independent radiologic or pathologic confirmation is described in the study design

What the number does not mean:

• It does not mean 84.4% of patients experienced tumor reduction
• It does not mean 84.4% had improved survival compared to a control group
• It does not apply to the full enrolled population of 197 patients; those who dropped out are not accounted for in this figure
• It does not isolate the effect of ivermectin-mebendazole from concurrent standard-of-care treatments patients may have been receiving

Survivorship bias at work:

Patients who felt well enough to complete six months of follow-up are systematically different from those who did not — likely healthier at baseline or more adherent, which artificially inflates perceived benefit rates.

A useful analogy for clinical framing: A patient who takes a new supplement and also feels better while simultaneously receiving chemotherapy cannot reliably attribute their improvement to the supplement. Without randomization and objective endpoints, the 84.4% figure is a compelling data point that cannot be causally interpreted. This is precisely why CAC invests in properly designed trials — because patients deserve findings that can actually be trusted and acted upon. Reviewing what the science actually says about ivermectin as a potential cancer treatment helps place individual study statistics in their proper evidence-based context.

---

The Anticancer Research Expression of Concern: Data Verifiability, Statistical Reliability, and Ethical Oversight Questions

Shortly after the Hulscher et al. paper was published, Anticancer Research issued a formal Expression of Concern (EOC) about journal flagging its own recently published paper. For patients and caregivers who came across this study on social media, this context is essential.

The EOC cited three primary concern domains:

1. Data verifiability: Questions were raised about the extent to which the reported patient data could research, independent auditability of raw data is a cornerstone of scientific reported figures accurately reflected the underlying data.

3. Ethical oversight: The EOC raised questions about whether appropriate institutional review board (IRB) or equivalent oversight was be interpreted with significant additional caution

• The journal is signaling to the scientific community that the paper’s findings may not be reliable
• Downstream citations of this paper in media, social platforms, or patient advocacy contexts should carry this caveat prominently

Whether your oncologist, a family member, or a patient group has shared this study with you, they need to know that its own publisher has formally flagged these unresolved integrity questions. That context-based conversation about your care. CAC’s position is that patients deserve this information fully disclosed — which is why we are providing it, even as we continue to sponsor independent research into these same compounds through properly designed clinical trials.

---

Selling the Product Studied? The Wellness Company’s Commercial Role Explained

One As a patient or caregiver, you have every right to know who produced the research you are reading and what financial interests they hold.

The conflict of interest chain:

• All 12 listed authors of the study are affiliated with and/or compensated by The Wellness Company (TWC) and/or the McCullough Foundation
• The Wellness Company is the sole commercial seller of the compounded ivermectin-mebendazole formulation that was with direct financial ties to the commercial entity that profits from the product’s adoption

Why this matters for your decision-making:

• Conflict of interest does not automatically invalidate research findings, but it represents a significant source of potential bias at every stage of study design and reporting
• The combination of: (a) industry-exclusive authorship, (b) no independent replication, (c) self-reported outcomes, (d) observational design, and (e) an active Expression of Concern creates a layered risk profile that should give any evidence-based clinician — and any informed patient — serious pause

What responsible research independence looks like:

Legitimate industry-sponsored research typically involves independent academic investigators, data safety monitoring boards, and arms-length analysis — structural safeguards designed to ensure that findings reflect reality rather than commercial interest. The structural arrangement in the Hulscher study — in which the authorship team is entirely drawn from the organization selling the studied product — falls outside standard research independence norms. Patients and caregivers who want to evaluate cancer treatment claims and find reliable information will find that assessing authorship conflicts of interest is one of the most important skills in navigating today’s information landscape.

---

NCI Ivermectin Research vs. the Hulscher Study: Two Completely Different Things

A common point of confusion circulating among patients and caregivers is the conflation of the Hulscher et al. commercial-interest study with separate, independent preclinical research conducted by or supported by the National Cancer Institute (NCI) into ivermectin’s potential antously for your decision-making.

What NCI-associated preclinical research has examined:

• Ivermectin’s effects on cancer cell lines in vitro (in laboratory dishes)
• Animal model experiments exploring potential mechanisms including P-glycoprotein inhibition, mitochondrial dysfunction in cancer cells, and modulation of signaling pathways such as WNT and PAK1
• Computational and pharmacological modeling of ivermectin’s interactionslinical laboratory findings do not translate automatically — or reliably — into human clinical benefit
• Cell line and animal model results regularly fail to replicate in human trials
• The biological plausibility that preclinical research suggests is not evidence of clinical efficacy

The critical translation gap:

The history of oncology drug development is filled with compounds that showed extraordinary promise in preclinical models and failed in human trials. This is precisely why CAC invests in properly designed clinical trials: because the only way to close the gap between promising biology and proven patient benefit is rigorous human investigation. The NCI’s exploration of ivermectin’s mechanism represents early-stage scientific inquiry that CAC views as genuinely encouraging — but it is not a clinical endorsement, and presenting NCI preclinical research and the Hulscher commercial study as a unified body of evidence is scientifically inaccurate and potentially misleading to patients navigating real treatment decisions. Understanding could ivermectin ever become part of an approved cancer therapy in the future helps clarify why preclinical signals, while encouraging, represent only the earliest stage of a long investigational process.

---

The Only Registered Human Ivermectin Oncology Trial (NCT05318469): What Is Actually Known

ClinicalTrials.gov identifier NCT05318469 represents the one formally registered, prospective human oncology trial examining ivermectin in a cancer context as of this writing. It is investigating ivermectin in combination with checkpoint inhibitor immunotherapy for metastatic triple-negative breast cancer (TNBC) — an aggressive and difficult-to-treat malignancy with limited standard options. For patients and caregivers who believe in the potential of these compounds, this kind of registered, rigorously designed trial is the right path forward — distinguish this from the Hulscher study:**

• Registered on ClinicalTrials.gov, establishing independent public accountability for design and outcomes
• Prospective design with defined primary and secondary endpoints
• Specific, defined patient population (metastatic TNBC) rather than a heterogeneous cancer mix
• Combination with an established